Quarterly report pursuant to Section 13 or 15(d)

Supplemental Equity and Accumulated Other Comprehensive Income (Loss) - Changes in Accumulated Other Comprehensive Income (Loss), Net of Tax (Details)

v3.22.1
Supplemental Equity and Accumulated Other Comprehensive Income (Loss) - Changes in Accumulated Other Comprehensive Income (Loss), Net of Tax (Details) - USD ($)
$ in Thousands
 9 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Balance $ 1,562,971  
Balance 1,714,376  
AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]    
Balance (6,193) $ (13,253)
Other comprehensive income (loss) before reclassifications, net of taxes, attributable to Bio-Techne 7,757 (13)
Reclassification from loss on derivatives to interest expense, net of taxes, attributable to Bio-Techne(1) 3,988 5,503
Balance 5,552 (7,763)
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]    
Balance (51,098) (83,946)
Other comprehensive income (loss) before reclassifications, net of taxes, attributable to Bio-Techne (9,599) 27,686
Reclassification from loss on derivatives to interest expense, net of taxes, attributable to Bio-Techne(1)   0
Balance (60,697) (56,260)
AOCI Attributable to Parent [Member]    
Balance (57,291) (97,199)
Other comprehensive income (loss) before reclassifications, net of taxes, attributable to Bio-Techne (1,842) 27,673
Reclassification from loss on derivatives to interest expense, net of taxes, attributable to Bio-Techne(1) 3,988 5,503
Balance $ (55,145) $ (64,023)